by The global Gene Synthesis market size is expected to be worth around US$ 10.58 billion by 2030, according to a new report by Vision Research Reports.
The global Gene Synthesis market size was valued at US$ 2.47 billion in 2020 and is anticipated to grow at a CAGR of 19.1% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39078
Growth Factors
Gene synthesis space is offering enormous potential for new biological functionality. This has resulted in the introduction of supportive government policies associated with synthetic biology, thereby driving the market.
Industry participants strive for developing proprietary and new technologies to strengthen their market presence. Furthermore, the establishment of organizations and forums helps encourage researchers to opt and study genetic engineering-related concepts and develop innovative technologies, which is also a notable growth driver of this space.
Considering this space as a lucrative source of revenue, companies are focusing on collaborations with various universities for on-site training, online workshops, and sponsored projects to boost their expertise portfolio. This is also expected to generate interest among research professionals by helping them realize the potential of this field and therefore spurring adoption in the market.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 10.58 billion by 2030 |
| Growth Rate | CAGR of 19.1% From 2021 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Method, Service, Application, End use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | GenScript; GENEWIZ; Boster Biological Technology; Twist Bioscience; ProteoGenix; Biomatik; ProMab Biotechnologies, Inc.; Thermo Fisher Scientific, Inc.; Integrated DNA Technologies, Inc.; OriGene Technologies, Inc. |
By Method Analysis
The solid-phase synthesis segment captured the maximum revenue share of more than 36% in 2020 owing to the highest adoption rate over the past few years. Also, the high accuracy of this method further boosts its deployment among the therapy developers and research settings.
PCR- and chip-based methods are anticipated to register significant CAGRs over the forecast period. These methods allow the synthesis of larger fragments at a lower rate, resulting in their increased usage.
By Service Analysis
The antibody DNA synthesis segment led the market with a revenue share of more than 60% in 2020. The presence of a substantial number of market players offering services for antibody DNA synthesis has resulted in the dominance of this segment.
Companies are offering services to pharma/biotech companies and research institutions to allow cloning and synthesis of antibody heavy/light chain sequences into any custom vector. On the other hand, the viral gene synthesis segment is estimated to register the fastest CAGR from 2021 to 2028 owing to the increasing virus vector-related R&D activities.
Companies are engaged in the synthesis of all non-structural and structural protein genes or gene fragments of the SARS-CoV-2. This has accelerated the acquisition of the virus recombinant proteins and has encouraged the research of protein structural biology of the virus particles.
By Application Analysis
The gene & cell therapy development segment accounted for the largest revenue share of more than 35% in 2020. This is anticipated to continue expanding the pipeline of advanced therapies for treating chronic conditions.
Academic institutions and companies across the globe are actively engaged in the development of new therapies, which are likely to boost the demand for services in this market.
the companies are also focusing on investments and funding to extend their capabilities for stem cell therapies and regenerative medicines. On the other hand, the vaccine development segment is anticipated to witness the fastest CAGR from 2021 to 2028 due to the rising concerns regarding future pandemics.
By End-use Analysis
The academic and government research institutes segment dominated the global market in 2020 accounting for a revenue share of over 54%. The segment is estimated to expand further at the fastest CAGR from 2021 to 2028 owing to the high usage of gene synthesis services in research settings.
The biotechnology & pharmaceutical companies segment is anticipated to witness notable growth during the forecast period. Increasing usage of synthesis biology by biotech companies for the development of novel disease management modalities is expected to bolster the segment growth.
By Regional Analysis
North America accounted for the largest revenue share of more than 38% in 2020 due to the presence of major players and supportive government initiatives pertaining to the training and implementation of synthetic biology programs.
Asia Pacific is estimated to register the fastest CAGR from 2021 to 2028. This can be attributed to the rising investments by global companies in the regional market. Moreover, the presence of some key companies in emerging nations, such as China and India, contributes to the market growth.
Key Players
- GenScript
- Brooks Automation, Inc. (GENEWIZ)
- Boster Biological Technology
- Twist Bioscience
- ProteoGenix
- Biomatik
- ProMab Biotechnologies, Inc.
- Thermo Fisher Scientific, Inc.
- Integrated DNA Technologies, Inc.
- OriGene Technologies, Inc.
Market Segmentation
- By Method
- Solid-phase Synthesis
- Chip-based Synthesis
- PCR-based Enzyme Synthesis
- By Service
- Antibody DNA Synthesis
- Viral DNA Synthesis
- Others
- By Application
- Gene & Cell Therapy Development
- Vaccine Development
- Disease Diagnosis
- Others
- By End-use
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Asia Pacific
- Japan
- China
- South Korea
- India
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Application Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Gene Synthesis Market, By Method
7.1. Gene Synthesis Market, by Method, 2021-2030
7.1.1. Solid-phase Synthesis
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Chip-based Synthesis
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. PCR-based Enzyme Synthesis
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Gene Synthesis Market, By Service
8.1. Gene Synthesis Market, by Service, 2021-2030
8.1.1. Antibody DNA Synthesis
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Viral DNA Synthesis
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Gene Synthesis Market, By Application
9.1. Gene Synthesis Market, by Application, 2021-2030
9.1.1. Gene & Cell Therapy Development
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Vaccine Development
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Disease Diagnosis
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Gene Synthesis Market, By End-use
10.1. Gene Synthesis Market, by End-use, 2021-2030
10.1.1. Biotechnology & Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Academic & Government Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Contract Research Organizations
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Gene Synthesis Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Method (2017-2030)
11.1.2. Market Revenue and Forecast, by Service (2017-2030)
11.1.3. Market Revenue and Forecast, by Application (2017-2030)
11.1.4. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Method (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Service (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Method (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Service (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Method (2017-2030)
11.2.2. Market Revenue and Forecast, by Service (2017-2030)
11.2.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Method (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Service (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Method (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Service (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Method (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Service (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Method (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Service (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Method (2017-2030)
11.3.2. Market Revenue and Forecast, by Service (2017-2030)
11.3.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Method (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Service (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Method (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Service (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Method (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Service (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Method (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Service (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Method (2017-2030)
11.4.2. Market Revenue and Forecast, by Service (2017-2030)
11.4.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Method (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Service (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Method (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Service (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Method (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Service (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Method (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Service (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Method (2017-2030)
11.5.2. Market Revenue and Forecast, by Service (2017-2030)
11.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Method (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Service (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Method (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Service (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. GenScript
12.1.1. Company Overview
12.1.2. Method Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Brooks Automation, Inc. (GENEWIZ)
12.2.1. Company Overview
12.2.2. Method Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Boster Biological Technology
12.3.1. Company Overview
12.3.2. Method Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Twist Bioscience
12.4.1. Company Overview
12.4.2. Method Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. ProteoGenix
12.5.1. Company Overview
12.5.2. Method Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Biomatik
12.6.1. Company Overview
12.6.2. Method Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ProMab Biotechnologies, Inc.
12.7.1. Company Overview
12.7.2. Method Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Thermo Fisher Scientific, Inc.
12.8.1. Company Overview
12.8.2. Method Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Integrated DNA Technologies, Inc
12.9.1. Company Overview
12.9.2. Method Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. OriGene Technologies, Inc.
12.10.1. Company Overview
12.10.2. Method Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39078
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
